CuResponse
Tel Aviv-yafo
About CuResponse
Curesponse is a medical company developing a three-dimensional tissue culture system for modeling cancer growth and drug response. The company's technology represents the next step in personalized cancer medicine, moving prediction capabilities beyond genomics and into the world of functional response on living patient cells. The platform preserves the cancer tissue architecture, including the vasculature and immune system, accurately reflecting the cancer growth found in the body. Curesponse’s cutting edge functional platform will match the correct drug to the patient's cancer, improving survival and saving unnecessary medical interventions. The company is harnessing the technology to create a personalized cancer diagnostic assay that can be used to determine the drug response for a specific individual's tumor type.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $6.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Jun 2020)
- Website: curesponse.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Medical, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/curesponse-160746 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.